Home > Insider Trading > Filing (0001127602-22-024595)

Filing Details

Accession Number:: 0001127602-22-024595
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-11-01 16:28:33
Reporting Period:: 2022-10-28

Accepted Time:: 2022-11-01 16:28:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
310158	Merck & Co. Inc.	MRK	Pharmaceutical Preparations (2834)	221918501

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1737231	Jennifer Zachary	Merck &Amp; Co., Inc. 126 East Lincoln Avenue Rahway NJ 07065	Evp, General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-10-28	68,367	$0.00	123,015	No	4	M	Direct
Common Stock	Acquisiton	2022-10-28	51,884	$0.00	174,899	No	4	M	Direct
Common Stock	Acquisiton	2022-10-28	28,396	$0.00	203,295	No	4	M	Direct
Common Stock	Disposition	2022-10-28	99,768	$99.07	103,527	No	4	S	Direct
Common Stock	Disposition	2022-10-28	65,487	$99.85	38,040	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-10-28	68,367	$0.00	68,367	$77.62
Common Stock	Stock Option (Right to Buy)	Disposition	2022-10-28	51,884	$0.00	51,884	$75.36
Common Stock	Stock Option (Right to Buy)	Disposition	2022-10-28	28,396	$0.00	28,396	$73.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2020-05-03	2029-05-02	No	4	M	Direct
25,946	2021-05-01	2030-04-30	No	4	M	Direct
56,792	2022-05-04	2031-05-03	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.5500 to $99.4900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.6100 to $100.3600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Holdings include shares acquired in dividend reinvestment transactions.
Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.